Predicting novel drug candidates against Covid-19 using generative deep neural networks

Santhosh Amilpur1, Raju Bhukya1

  • 1National Institute of Technology, Waranagl, 506004, India.

Insights

This study introduces a novel drug discovery method using a long short-term memory (LSTM) model to generate potential COVID-19 treatments. The AI-designed molecules show high binding affinity to the novel Coronavirus protease, offering promising therapeutic candidates.

Area of Science:

  • Computational chemistry
  • Artificial intelligence in drug discovery
  • Virology

Background:

  • The COVID-19 pandemic necessitates rapid development of effective treatments.
  • Traditional drug discovery is time-consuming, highlighting the need for accelerated methods.
  • Targeting the novel Coronavirus 3CL protease is a key strategy for therapeutic intervention.

Purpose of the Study:

  • To develop an AI-driven approach for generating novel drug candidates against the novel Coronavirus.
  • To identify molecules with high binding affinity to the 3CL protease using a long short-term memory (LSTM) model.
  • To assess the potential of generated molecules as therapeutic agents for COVID-19.

Main Methods:

  • Utilized a long short-term memory (LSTM) deep learning model for de novo molecule generation.
  • Employed in silico screening and molecular docking simulations to evaluate binding affinities.
  • Focused on the 3CL protease (3CLPro) as the primary therapeutic target.

Main Results:

  • The LSTM model successfully generated novel molecules with properties similar to trained datasets.
  • 80% of generated molecules exhibited a docking free energy below -5.8 kcal/mol.
  • The top candidate molecule demonstrated a superior binding affinity (-8.5 kcal/mol) compared to Remdesivir.

Conclusions:

  • The proposed AI method effectively generates promising drug candidates for COVID-19.
  • Generated molecules show significant potential for targeting the novel Coronavirus 3CL protease.
  • This approach offers a faster alternative for discovering novel antiviral therapeutics.